Technology

Astellas Pharma announced that the company will now make trial data available through an independent website that enables researchers to request and access clinical trial data.

Pfizer announced on Feb. 5, 2015 that it is acquiring injectable, infusible, and biosimilar manufacturer Hospira for nearly $17 billion after the assumption of debt.

The pharma, medical and biotech sector accounted for the top three announced deals of the year in the EMEA region in 2014.

The French pharmaceutical market is forecast to grow at a "tepid" CAGR of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, according to GlobalData.

Pharma and healthcare are among the many areas being viewed with increasing attention inside and outside Greece, following the victory in the country’s elections of the radical left-wing, anti-austerity Syriza party.

AstraZeneca (AZ) and The University of Texas MD Anderson Cancer Center (Houston, TX) have announced a multi-year, strategic research collaboration.

Findings from the joint report on the occurrence of antimicrobial resistance in bacteria from humans and food-producing animals.

The European Hantavirus diagnostics market is growing at a CAGR of 5.8 percent, outperforming the U.S. market, which registered 3.7 percent.

GlaxoSmithKline (GSK) announced on January 26 that it will freeze vaccine prices for Gavi-eligible countries for up to 10 years after the country graduates from Gavi support.

Bill Drummy presents the highlights (what he will admit to, anyway) from this month's International Consumer Electronics Show in Las Vegas.

Glaxo SmithKline (GSK) has announced that Sir Philip Hampton has been appointed Chairman of the Nominations Committee, effective today (January 27).

Franz Humer, former CEO and chairman of Roche, has joined BIAL, Portugal's largest pharma company, as a non-executive board member.

Sanofi has agreed to pay its former CEO Chris Viehbacher a total of Euro 4.44 million ($5.06 million).

The healthcare landscape in Asia-Pacific is expected to continue grow strongly in 2015, according to a report by Frost & Sullivan.

CPhI Worldwide is launching an international advisory board.

The value of the Colorectal Cancer (CRC) therapeutics market will increase from $8.3 billion in 2013 to $9.4 billion by 2020, according to a report from GBI Research.

With the FDA approving an all-time record number of orphan drugs during 2014, the pricing of these treatments is set to come under increased scrutiny.

Bristol-Myers Squibb (BMS) has named former chief operating officer Giovanni Caforio as the company’s new CEO.

Investigators and sponsors of clinical trials will have to make more detailed data available following study completion, according to a new report from an Institute of Medicine (IOM) expert panel.

Healthcare and pharma executives have recovered their optimism in the past year, according to an EIU survey.

Pharm Exec’s annual report highlights the key scientific, commercial, and reputational trends shaping the industry in the year ahead.

Frost & Sullivan has released its "Drug Launch and Phase 3 Trial Watch List for Top Therapy Areas for 2015".

WHO's tuberculosis program leader and the CFO of Ultragenyx jojn Board of Directors.

Richard Bergström, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) has called for "homogenization of European HTA bodies and regulation"

FDA’s Center for Drug Evaluation and Research (CDER) has released its guidance agenda for 2015.

CVS confirmed this week that it will exclusively offer Gilead's Harvoni and Sovaldi to members through its CVS/Caremark commercial, exchange, Medicare Part D, and Medicaid formularies.

Oxford University doctors and scientists have begun the first safety trial of Janssen's experimental Ebola vaccine in the UK.

Big Pharma and foreign investors are "flocking" to Turkey to capitalize on its encouraging economic policies, according to new analysis from Frost & Sullivan.

The type 2 diabetes treatment market in Asia-Pacific (APAC) will rise in value from an estimated $6.5 billion in 2013 to $10.5 billion by 2020, representing a modest Compound Annual Growth Rate (CAGR) of 7.1%.

Isis Pharmaceuticals has announced that it has entered into a collaboration with Janssen Biotech to develop three antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract.